Global capabilities
Delivering value beyond the test result
At Mayo Clinic Laboratories, laboratory medicine is about more than a test result — it’s about everything that contributes to providing answers for your patients. We develop individualized support solutions for each client that extend through all aspects of the relationship to ensure the delivery of answers, not just results.
Specialized testing areas include:
Global logistics and shipping
We develop unique relationships with each client to individualize logistics support, which is coordinated by a local team who ensures a seamless process before the first patient specimen is sent. Our specialists collaborate with packaging suppliers to create unique solutions that extend the stability of specimens traveling around the world.
These experts ensure specimens are handled carefully and efficiently through close connections to shipping carriers. The air carriers we work with are experienced with processing clinical specimens.
Optimized, expeditious processing
We recognize many medical conditions have a window of opportunity for the best possible outcomes. Our tests and processes are optimized to better serve patients and deliver results with outcomes in mind. We do not triage specimens across a network of labs or use a batch-testing business model. Result turnaround times are expedited by:
- Running tests continuously – your samples are processed alongside those from Mayo Clinic.
- A testing approach that incorporates comprehensive panels and algorithms when appropriate.
- Utilization of Lean and Six Sigma processes.
Reliable connectivity
We offer technology solutions to help our clients connect to us, including a secure online portal with interfacing capabilities that allows you to easily order tests and receive results. Our solutions include:
- Client-friendly test ordering through MayoLINK, which is available in eight languages.
- Expansive website with links to our open- access test catalog, which is updated daily and features comprehensive clinical information, including specimen requirements; clinical and interpretative information; performance; sample test reports; setup files; and pricing.
- 30 country-specific toll-free numbers.
News and updates
The latest
Recognize the motivations and barriers of first-time blood donors and work to retain them for sustainable future donations.
This week's research roundup feature: C3 glomerulopathy (C3G) is a rare disease resulting from dysregulation of the alternative pathway of complement. C3G includes C3 glomerulonephritis (C3GN) and dense deposit disease (DDD), both of which are characterized by bright glomerular C3 staining on immunofluorescence studies. However, on electron microscopy (EM), DDD is characterized by dense osmiophilic mesangial and intramembranous deposits along the glomerular basement membranes (GBM), while the deposits of C3GN are not dense. Why the deposits appear dense in DDD and not in C3GN is not known. We performed laser microdissection (LCM) of glomeruli followed by mass spectrometry (MS) in 12 cases each of DDD, C3GN, and pretransplant kidney control biopsies.
Dr. Linda Hasadsri’s firsthand encounter with the genetic tests she’s helped develop has provided rare insight into testing quality and implications, enhancing their ability to advocate for the value of testing and infusing their work with deep empathy.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss the Food and Drug Administration’s (FDA) progress on making a final rule around regulating laboratory-developed tests (LDTs).
William Morice II, M.D., Ph.D., president and chief executive officer of Mayo Clinic Laboratories, is a contributing author on Nasdaq.com. In his first article, Dr. Morice reflects on the diagnostic landscape and predicts trends that could influence the market in 2024.
This week's research roundup feature: Variants of uncertain significance (VUSs) in BRCA2 are a common result of hereditary cancer genetic testing. While more than 4,000 unique VUSs, comprised of missense or intronic variants, have been identified in BRCA2, the few missense variants now classified clinically as pathogenic or likely pathogenic are predominantly located in the region encoding the C-terminal DNA binding domain (DBD). We report on functional evaluation of the influence of 462 BRCA2 missense variants affecting the DBD on DNA repair activity of BRCA2 using a homology-directed DNA double-strand break repair assay.
The CORE communication approach, designed by Mayo Clinic Experience Training, Education & Coaching, is a foundational method to help navigate human-centered communication that emphasizes perspective-taking, growth in learning, and positive behavior changes.
This page includes updates posted to Mayo Clinic Labs during the month of February.
In this episode of “Lab Medicine Rounds,” host Justin Kreuter, M.D., speaks with operations administrator Mark Brown to discuss the significance of collaborating with administrators.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to honor Black History Month. They reflect on important advancements in healthcare and laboratory medicine that were led by Black healthcare professionals and scholars. They also discuss health inequities that impact communities throughout the United States.
This week's research roundup feature: Both targeted therapies and immunotherapies provide benefit in resected Stage III melanoma. We hypothesized that the combination of targeted and immunotherapy given prior to therapeutic lymph node dissection (TLND) would be tolerable and drive robust pathologic responses.
In this episode of Mayo Clinic Laboratories’ “Leveraging the Laboratory” podcast, host Jane Hermansen, outreach manager at Mayo Clinic Laboratories, speaks with outreach solutions strategists Ellen Dijkman Dulkes and Brianne Newton. They discuss how an outreach program can work with its customers on process improvements by using periodic visits and data-driven discussions.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Stefan Grebe, M.D., Ph.D., co-director of the Clinical Mass Spectrometry and Test Development Laboratory in the Department of Laboratory Medicine and Pathology, and Irina Bancos, M.D., consultant in the Division of Endocrinology, Diabetes, and Metabolism with a joint appointment in biochemistry and immunology. They discuss the diagnosis and management of adrenal gland tumors.